Brookline Capital II Files S-1 for $100M SPAC IPO Targeting Healthcare, Defense

TL;DR

**Avoid BCAC's IPO; the sponsor's cheap founder shares and anti-dilution rights spell significant dilution for public investors, making this a high-risk bet.**

AI Summary

Brookline Capital Acquisition Corp II (BCAC) filed an S-1 for an initial public offering of 10,000,000 units at $10.00 per unit, aiming to raise $100,000,000. Each unit comprises one Class A ordinary share and one right to receive one-tenth of a Class A ordinary share upon business combination. The SPAC intends to target companies in the healthcare and defense technology industries. The sponsor, Brookline Capital Holdings II, LLC, will purchase 236,175 placement units for $2,361,750 and holds 4,583,916 Class B ordinary shares acquired for $25,000, or approximately $0.005 per share, which could lead to significant dilution for public shareholders due to anti-dilution provisions. The company will deposit $100,000,000 into a trust account, with funds released upon a business combination or redemption within 24 months. Executive officers are affiliates of Brookline Capital Markets, the sole book-running manager, creating a FINRA Rule 5121 conflict of interest, necessitating a qualified independent underwriter.

Why It Matters

This S-1 filing signals Brookline Capital Acquisition Corp II's entry into the SPAC market, offering investors a new vehicle to potentially access high-growth companies in healthcare and defense technology. However, the significant dilution risk from the sponsor's founder shares, acquired at a nominal $0.005 per share, could erode public shareholder value, making due diligence critical. The inherent conflicts of interest due to the underwriter's affiliation with the SPAC's executive officers also raise governance concerns, potentially impacting the fairness of future transactions. This offering adds to the competitive landscape of SPACs vying for attractive private targets, potentially driving up acquisition valuations.

Risk Assessment

Risk Level: high — The risk level is high due to the substantial dilution potential from the sponsor's 4,583,916 Class B ordinary shares, acquired for a nominal $25,000 (approximately $0.005 per share), compared to the public offering price of $10.00 per unit. Additionally, the anti-dilution rights of the Class B shares could result in a greater than one-to-one conversion ratio, further diluting public shareholders' interests. The conflict of interest arising from the executive officers' affiliation with the sole book-running manager, Brookline Capital Markets, also presents a heightened risk.

Analyst Insight

Investors should exercise extreme caution and consider avoiding this IPO due to the significant dilution risk from the sponsor's founder shares and their anti-dilution provisions. Thoroughly evaluate the potential target industries (healthcare and defense technology) and the management team's track record, but prioritize the substantial equity dilution before committing capital.

Financial Highlights

debt To Equity

0.0

revenue

$0

operating Margin

N/A

total Assets

$100,000,000

total Debt

$0

net Income

$0

eps

$0.00

gross Margin

N/A

cash Position

$100,000,000

revenue Growth

N/A

Key Numbers

• $100,000,000 — Total IPO proceeds (Amount to be raised from the offering of 10,000,000 units at $10.00 each.)
• 10,000,000 — Number of units offered (Each unit priced at $10.00.)
• $10.00 — Offering price per unit (Price for each unit consisting of one Class A ordinary share and one right.)
• 236,175 — Placement units purchased by sponsor (Purchased by Brookline Capital Holdings II, LLC at $10.00 per unit.)
• $2,361,750 — Aggregate purchase price for placement units (Paid by the sponsor for 236,175 placement units.)
• 4,583,916 — Class B ordinary shares held by sponsor (Acquired for $25,000, representing significant potential dilution.)
• $0.005 — Cost per Class B ordinary share for sponsor (Nominal price paid by the sponsor, highlighting dilution risk.)
• 24 months — Timeframe to complete business combination (If not completed, public shares will be redeemed.)
• $15,000 — Monthly payment to sponsor (For office space, utilities, and shared personnel support services.)
• $1,500,000 — Maximum working capital loans from sponsor (Convertible into units at $10.00 per unit at lender's option.)

Key Players & Entities

• Brookline Capital Acquisition Corp II (company) — Registrant and SPAC offering units
• Brookline Capital Holdings II, LLC (company) — Sponsor of the SPAC
• Patrick A. Sturgeon (person) — Chief Executive Officer of Brookline Capital Acquisition Corp II
• Brookline Capital Markets (company) — Sole book-running manager and representative of the underwriters
• Nelson Mullins Riley & Scarborough LLP (company) — Legal counsel for the registrant
• Ogier (Cayman) LLP (company) — Legal counsel for the registrant
• Winston & Strawn LLP (company) — Legal counsel for the registrant
• Continental Stock Transfer & Trust Company (company) — Trustee for the trust account
• BlackRock Advisors, LLC (company) — Investment manager for the trust account
• FINRA (regulator) — Regulatory body citing conflict of interest

FAQ

Risk Factors

• Dilution from Sponsor Shares [high — financial]: The sponsor acquired 4,583,916 Class B ordinary shares for a nominal $25,000, or approximately $0.005 per share. These shares are convertible into Class A ordinary shares on a 1:1 basis, subject to anti-dilution adjustments. This low acquisition cost for a significant number of shares presents a substantial dilution risk for public shareholders, especially if the share price increases.
• Sponsor Working Capital Loans [medium — financial]: The sponsor may provide up to $1,500,000 in working capital loans. These loans are convertible into units at $10.00 per unit at the lender's option. If the SPAC's share price is below $10.00 at the time of conversion, this could result in dilution for public shareholders as the sponsor receives units at a favorable price.
• FINRA Rule 5121 Conflict of Interest [high — regulatory]: Brookline Capital Markets, the sole book-running manager, is an affiliate of the SPAC's executive officers. This creates a conflict of interest under FINRA Rule 5121, requiring a qualified independent underwriter to conduct due diligence and participate in the offering. Failure to comply could lead to regulatory sanctions.
• Limited Operating History and Target Industry Risks [medium — operational]: As a newly formed SPAC, BCAC has no operating history. Its target industries, healthcare and defense technology, are subject to rapid technological change, intense competition, and significant regulatory hurdles. The success of the business combination is highly dependent on identifying and executing a suitable target within these dynamic sectors.
• Redemption Risk and Trust Account Depletion [medium — financial]: Public shareholders have the right to redeem their shares for a pro rata portion of the trust account if a business combination is not completed within 24 months. If a significant number of redemptions occur, it could reduce the capital available for the target company, potentially impacting the viability of the business combination or the post-combination entity's financial health.
• Sponsor Fees and Expenses [low — operational]: The sponsor will receive monthly payments of $15,000 for administrative services, totaling $180,000 annually, plus reimbursement for certain expenses. While not excessive, these costs reduce the net proceeds available for the business combination.

Industry Context

The healthcare and defense technology industries are characterized by high growth potential, significant innovation, and substantial regulatory oversight. Healthcare is driven by an aging population, advancements in biotechnology, and evolving treatment modalities. Defense technology benefits from geopolitical tensions and the increasing reliance on advanced surveillance, cybersecurity, and unmanned systems. Both sectors are capital-intensive and require deep technical expertise, making them attractive but challenging targets for SPACs.

Regulatory Implications

The involvement of Brookline Capital Markets as the sole book-running manager, an affiliate of the SPAC's management, triggers FINRA Rule 5121. This necessitates the appointment of a qualified independent underwriter to mitigate conflicts of interest and ensure fair dealing. Failure to comply with this rule could result in regulatory penalties and impact the offering's validity.

What Investors Should Do

1. Scrutinize the sponsor's dilution potential arising from the low-cost Class B shares and conversion terms of any working capital loans.
2. Evaluate the necessity and effectiveness of the qualified independent underwriter due to the FINRA Rule 5121 conflict of interest.
3. Assess the SPAC's ability to identify and successfully merge with a viable target in the competitive healthcare or defense technology sectors within the 24-month timeframe.
4. Consider the redemption risk and its potential impact on the capital available for the target company post-combination.

Glossary

SPAC

Special Purpose Acquisition Company. A shell company that raises capital through an IPO to acquire an existing company. (BCAC is a SPAC seeking to acquire a target company in the healthcare or defense technology sectors.)

Units

The securities offered in the IPO, each consisting of one Class A ordinary share and one right. (The IPO is structured around the sale of these units to raise capital.)

Rights

A warrant that entitles the holder to receive one-tenth of a Class A ordinary share upon the completion of a business combination. (These rights add potential future dilution and are part of the unit structure.)

Class B ordinary shares

Shares held by the sponsor, typically convertible into Class A shares and carrying voting rights, often acquired at a nominal price. (The sponsor's Class B shares represent a significant potential dilution risk due to their low acquisition cost and conversion terms.)

Trust Account

A segregated account holding the IPO proceeds, which can only be used for a business combination or redemptions. (The $100,000,000 raised will be deposited here, with funds released upon a business combination or redemption.)

Business Combination

The acquisition of a target company by the SPAC. (The primary objective of BCAC; failure to complete one within 24 months triggers redemption.)

Redemption

The process by which public shareholders can elect to receive their pro rata share of the trust account funds if a business combination is not completed. (A key risk for SPACs, as high redemptions can deplete capital.)

FINRA Rule 5121

A Financial Industry Regulatory Authority rule governing offerings involving conflicts of interest, requiring a qualified independent underwriter. (Applicable here due to the affiliation between the book-running manager and the SPAC's management, necessitating an independent underwriter.)

Year-Over-Year Comparison

As this is an initial S-1 filing for Brookline Capital Acquisition Corp II, there is no prior filing to compare key metrics against. The document outlines the proposed structure, fundraising goals, and initial risk factors associated with the formation and upcoming IPO of the SPAC.

Key Financial Figures

• $100,000,000 B — O COMPLETION, DATED DECEMBER 19, 2025 $100,000,000 Brookline Capital Acquisition Corp II 1
• $10.00 — ies. Each unit has an offering price of $10.00 and consists of one Class A ordinary sh
• $2,361,750 — nit, for an aggregate purchase price of $2,361,750. Each placement unit will be identical
• $0.005 — cquired for $ 25,000 , or approximately $0.005 per share. The Class B ordinary shares
• $25,000 — Team — Our sponsor paid an aggregate of $25,000, or approximately $0.006 per founder sh
• $0.006 — aggregate of $25,000, or approximately $0.006 per founder share, and, accordingly, yo
• $15,000 — our sponsor or its affiliate a total of $15,000 per month for office space, utilities a
• $300,000 — n of this offering, we will repay up to $300,000 in loans made to us by our sponsor to c
• $1,500,000 — unds as may be required to a maximum of $1,500,000 to fund our additional working capital
• $500,000 — 99,250,000 ____________ (1) Includes $500,000 in the aggregate, payable to the underw
• $250,000 — the closing of this offering and up to $250,000 in the aggregate that is payable in cas
• $100.0 million — ent units described in this prospectus, $100.0 million or $115.0 million if the underwriters'
• $115.0 million — d in this prospectus, $100.0 million or $115.0 million if the underwriters' over -allotment op
• $200,000 — anchise and income taxes, if any, up to $200,000 of interest per year to fund our workin
• $100,000 — d our working capital requirements, and $100,000 of interest for our dissolution expense

Filing Documents

• ea0269114-01.htm (S-1) — 4590KB
• ea026911401ex3-1_brookline.htm (EX-3.1) — 477KB
• ea026911401ex10-1_brookline.htm (EX-10.1) — 51KB
• ea026911401ex10-2_brookline.htm (EX-10.2) — 21KB
• ea026911401ex23-1_brookline.htm (EX-23.1) — 2KB
• ea026911401ex99-2_brookline.htm (EX-99.2) — 3KB
• ea026911401ex99-3_brookline.htm (EX-99.3) — 3KB
• ea026911401ex99-4_brookline.htm (EX-99.4) — 3KB
• ea026911401ex-fee_brookline.htm (EX-FILING FEES) — 24KB
• ex3-1_001.jpg (GRAPHIC) — 6KB
• ex3-1_002.jpg (GRAPHIC) — 51KB
• ex3-1_003.jpg (GRAPHIC) — 14KB
• ex23-1_001.jpg (GRAPHIC) — 9KB
• ex23-1_002.jpg (GRAPHIC) — 3KB
• 0001213900-25-123838.txt ( ) — 8605KB
• bcac-20251219_def.xml (EX-101.DEF) — 13KB
• bcac-20251219_lab.xml (EX-101.LAB) — 104KB
• bcac-20251219_pre.xml (EX-101.PRE) — 65KB
• bcac-20251219.xsd (EX-101.SCH) — 8KB
• ea0269114-01_htm.xml (XML) — 1065KB
• ea026911401ex-fee_brookline_htm.xml (XML) — 12KB

Risk Factors

Risk Factors 40 Enforcement of Civil Liabilities 79

Use of Proceeds

Use of Proceeds 81 Dividend Policy 85

Dilution

Dilution 86 Capitalization 89

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 90 Proposed Business 96 Management 125 Principal Shareholders 137 Certain Relationships and Related Party Transactions 139

Description of Securities

Description of Securities 142 Taxation 160 Underwriting (Conflicts of Interest) 170 Legal Matters 177 Experts 177 Where You Can Find Additional Information 177 Index to Financial Statements F-1 We are responsible for the information contained in this prospectus. We have not authorized anyone to provide you with different information, and we take no responsibility for any other information others may give to you. We are not, and the underwriters are not, making an offer to sell securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than the date on the front of this prospectus. i Table of Contents SUMMARY This summary only highlights the more detailed information appearing elsewhere in this prospectus. You should read this entire prospectus carefully, including the information under the section of this prospectus entitled "Risk Factors" and our financial statements and the related notes included elsewhere in this prospectus, before investing. Unless otherwise stated in this prospectus, or the context otherwise requires, references to: "Brookline" are to Brookline Capital Markets, a division of Arcadia Securities, LLC, the representative of the underwriters in this offering; "Class A ordinary shares" are to Class A ordinary shares of par value $0.0001 each in the capital of the Company; "Class B ordinary shares" are to Class B ordinary shares of par value $0.0001 each in the capital of the Company; "Companies Act" are t

View Full Filing

View this S-1 filing on SEC EDGAR